Shots:Ionis has reported P-III (CORE: n=617 & CORE2: n=446) trials data assessing olezarsen (50 or 80mg, SC, Q4W) vs PBO for 12mos. in adults with severe hypertriglyceridemia (sHTG); the US FDA’s sNDA submission expected by year endBoth studies met their 1EP, with CORE showing reduction in fasting triglycerides by 72% (80mg) & 63%…
